Aldosterone antagonists in the treatment of hypertension and target organ damage

被引：19

作者：

Rajagopalan S. ^{[1
]}

Pitt B. ^{[1
]}

机构：

[1] Division of Cardiology, L3119, Women's Hospital, Ann Arbor, MI 48109-0273

来源：

Current Hypertension Reports | 2001年 / 3卷 / 3期

关键词：

Aldosterone; Spironolactone; Mineralocorticoid Receptor; Mineralocorticoid; Eplerenone;

D O I：

10.1007/s11906-001-0046-2

中图分类号：

学科分类号：

摘要：

Mineralocorticoids mediate a number of effects besides regulation of fluid and electrolyte balance. Recent evidence has revealed several nontraditional roles, sites of synthesis, and action for these steroids. Aldosterone, the principal mineralocorticoid in humans, appears to be synthesized in physiologically relevant amounts in both the heart and the vasculature, and plays an important role in vessel wall and myocardial remodeling. The genomic effects of aldosterone are mediated through activation of the classic mineralocorti-coid receptor, whereas rapid nongenomic effects seem to involve a distinct receptor and result in activation of multiple downstream signaling pathways. Recently, several lines of evidence seem to suggest an important interaction between the nitric oxide and the aldosterone pathway in the adrenal gland and vasculature. The evolution of selective aldosterone receptor antagonists will help us understand the role that mineralocorticoids play in the pathogenesis of hypertension, heart failure, and atherosclerosis. Copyright © 2001 by Current Science Inc.

引用

页码：240 / 248

页数：8

共 58 条

[1]

Arriza J.L., Weinberger C., Cerelli G., Et al., Cloning of human mineralocorticoid receptor complementary DNA: Structural and functional kinship with the glucocorticoid receptor, Science, 237, pp. 268-275, (1987)

[2]

Patel P.D., Sherman T.G., Goldman D.J., Watson S.J., Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus, Mol Endocrinol, 3, pp. 1877-1885, (1989)

[3]

Trapp T., Holsboer F., Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping, Biochem Biophys Res Commun, 215, pp. 286-291, (1995)

[4]

Rogerson F.M., Fuller P.J., Mineralocorticoid action, Steroids, 65, pp. 61-73, (2000)

[5]

Rupprecht R., Arriza J.L., Spengler D., Et al., Transactivation and synergistic properties of the mineralocorticoid receptor: Relationship to the glucocorticoid receptor, Mol Endocrinol, 7, pp. 597-603, (1993)

[6]

Funder J.W., Pearce P.T., Smith R., Smith A.I., Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated, Science, 242, pp. 583-585, (1988)

[7]

White P.C., Mune T., Agarwal A.K., 11 beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess, Endocrinol Rev, 18, pp. 135-156, (1997)

[8]

Lombes M., Kenouch S., Souque A., Et al., The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase, Endocrinology, 135, pp. 834-840, (1994)

[9]

Halachmi S., Marden E., Martin G., Et al., Estrogen receptor-associated proteins: Possible mediators of hormone-induced transcription, Science, 264, pp. 1455-1458, (1994)

[10]

Couette B., Lombes M., Baulieu E.E., Rafestin-Oblin M.E., Aldosterone antagonists destabilize the mineralocorticosteroid receptor, Biochem J, 282, pp. 697-702, (1992)

← 1 2 3 4 5 6 →